A New Preoperative Scoring System for Predicting Aggressiveness of Non-Functioning Pancreatic Neuroendocrine Neoplasms
Authors:
- Tetsuya TakikawaTTTetsuya Takikawa
- Kazuhiro KikutaKKKazuhiro Kikuta
- Shin HamadaSHShin Hamada
- Kiyoshi KumeKKKiyoshi Kume
- Shin MiuraSMShin Miura
- Naoki YoshidaNYNaoki Yoshida
- Yu TanakaYTYu Tanaka
- Ryotaro MatsumotoRMRyotaro Matsumoto
- Mio IkedaMIMio Ikeda
- Fumiya KataokaFKFumiya Kataoka
- Akira SasakiASAkira Sasaki
- Hidehiro HayashiHHHidehiro Hayashi
Open Access
- 3 February 2022
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 12 (2) , 397
Abstract
The management of non-functioning pancreatic neuroendocrine neoplasms (NF-PanNENs) is still controversial. This study aimed to develop a new scoring system for treatment decisions at initial diagnosis based on the identification of the predictive factors for aggressive NF-PanNENs. Seventy-seven patients who had been pathologically diagnosed with NF-PanNENs were enrolled. We retrospectively reviewed 13 variables that could be assessed preoperatively. Univariate and multivariate stepwise logistic regression analyses were performed to identify factors for the aggressiveness of NF-PanNENs, and a scoring system was developed by assigning weighted points proportional to their β regression coefficient. Tumor size > 20 mm on contrast-enhanced computed tomography, tumor non-vascularity, and Ki-67 labeling index ≥5% on endoscopic ultrasound-guided fine-needle aspiration specimens were identified as independent factors for predicting the aggressiveness of NF-PanNENs. The new scoring system, developed using the identified factors, had an excellent discrimination ability, with area under the curve of 0.92 (95% CI, 0.85–0.99), and good calibration (p = 0.72, Hosmer-Lemeshow test). Ten-year overall survival rates in low-risk (0 point), intermediate-risk (1 to 2 points), and high-risk (3 to 4 points) groups were 100%, 90.9%, and 24.3%, respectively. This new scoring system would be useful for treatment decisions and prognostic prediction at initial diagnosis.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K21593)
- Kurokawa Cancer Research Foundation (N/A)
This publication has 59 references indexed in Scilit:
- Preoperative Identification of a Prognostic Factor for Pancreatic Neuroendocrine Tumors Using Multiphase Contrast-Enhanced Computed TomographyPancreas, 2016
- Surgical Resection Provides an Overall Survival Benefit for Patients with Small Pancreatic Neuroendocrine TumorsJournal of Gastrointestinal Surgery, 2015
- The usefulness of endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of pancreatic neuroendocrine tumors based on the World Health Organization classificationScandinavian Journal of Gastroenterology, 2014
- Observational Study of Natural History of Small Sporadic Nonfunctioning Pancreatic Neuroendocrine TumorsThe Journal of Clinical Endocrinology & Metabolism, 2013
- Population-Level Analysis of Pancreatic Neuroendocrine Tumors 2 cm or Less in SizeAnnals of Surgical Oncology, 2013
- Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumorSurgery, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine TumorsAnnals of Surgery, 2008
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy materialVirchows Archiv, 1975